Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study | OncLive
8:14
Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study | OncLive
Apr 16, 2025
onclive.com
See more
Static thumbnail place holder